search results for

refine results

sort by


result type


Press Releases

The shift toward value-based care in health industry

CNBC's Meg Tirrell reports on the biggest health issues and how industry leaders are thinking about the future of health care in America. David Gluckman, Lazard co-head of health care, weighs in.


Puma Biotech spikes after FDA support of breast cancer drug

CNBC's Meg Tirrell reports on Puma's stock spike after the FDA board votes in support of its breast cancer drug.


FDA panel votes in favor of Puma's breast cancer drug

CNBC's Meg Tirrell reports on the FDA approving Puma Biotech's breast cancer drug, which sent shares of the company higher.


Nuerocrine's Tourette's syndrome drug trial fails

CNBC's Meg Tirrell reports Neurocrine's stock fell after hours following reports it's drug trial for a new Tourette's medication had failed.


Vertex CEO: Our goal is to have one medicine for all cystic fibrosis patients

Jeff Leiden, Vertex Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about his company's cystic fibrosis drugs and the future for biotech and pharma under the current administration.


Amgen osteoporosis drug imperiled by safety concerns

CNBC's Meg Tirrell reports on Amgen stocks falling today after a drug risk.


What to watch at ASCO cancer conference

CNBC's Meg Tirrell reports on the major names making waves in cancer research ahead of the American Society of Clinical Oncology conference.


What the latest data on cancer research means for biotech stocks

CNBC's Meg Tirrell reports on the drug stocks reacting to the data dump. The "Fast Money" traders weigh in.


Johnson & Johnson analysts' day

CNBC's Meg Tirrell reports the latest out of Johnson & Johnson's analyst day, and discusses the company's growing pharmaceutical business.


Cancer data deluge set to move stocks

CNBC's Meg Tirrell reports on the biotech stocks to watch, including a new player Incyte, as well as Johnson and Johnson's analyst day and Amazon's pharmaceutical break in. "Fast Money Halftime Report" traders and Kevin O'Leary weigh in.